Navigation Links
Mersana Therapeutics Provides Clinical Update from Ongoing Phase 1 Study of XMT-1001 in Patients with Advanced Solid Tumors
Date:11/17/2009

CAMBRIDGE, Mass., Nov. 17 /PRNewswire/ -- Mersana Therapeutics, a platform-based cancer therapeutics company, announced today additional preliminary results from an ongoing Phase 1 study of its lead development candidate, XMT-1001, in patients with advanced solid tumors. The results were presented in a poster session at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics in Boston, MA November 15-19, 2009. XMT-1001 is a conjugate of the broad-spectrum cytotoxic camptothecin (CPT) that employs Mersana's Fleximer® platform.

XMT-1001 has continued to demonstrate promising tumor activity and favorable pharmacokinetic and tolerability profiles in the Phase 1 trial. Forty nine patients with refractory solid tumors have received 149 cycles of XMT-1001 at dose levels ranging from 1.0-85 mg CPT equivalents/m2. Twelve of 46 evaluable patients with advanced, refractory tumors demonstrated evidence of at least six weeks of stable disease. Nine of the 12 patients had prolonged stable disease for at least 12 weeks, including two patients for nine months. In addition, pharmacokinetic data for XMT-1001 have demonstrated dose proportional increases in exposure to the drug and confirms the formation of its release products according to the compound's design. The side-effect profile of XMT-1001 has been predictable and no toxicities associated with non-Fleximer-linked CPT or irinotecan, such as hemorrhagic cystitis or severe diarrhea, have been observed. The maximum tolerated dose (MTD) has not been reached and the Phase 1 study continues to accrue patients.

"We are very pleased to see that the data in this ongoing Phase 1 study for XMT-1001 continues to support our goal of establishing proof of concept fo
'/>"/>

SOURCE Mersana Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Mersana Therapeutics Reports Phase I Results for XMT-1001 in Patients with Solid Tumors at AACR-NCI-EORTC International Conference
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
(Date:1/15/2014)... GARDENS, Fla. , Jan. 15, 2014  In an unprecedented effort ... and TB in ambulances and other transport vehicles, an advanced and ... by rescue personnel for the first time. In ... contact with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... patent application concerning composition of matter, biological targets, mechanism ... cell death.  This patent application describes ... RNA molecules (VSRNAs) which interfere with the basic homeostatic ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Oct. 24, 2011 PhotoMedex , Inc. (NASDAQ: ... including the XTRAC® excimer laser ( www.XTRACLaser.com ), is offering ... XTRAC psoriasis treatments for children, an underserved population of ... presented in recognition of World Psoriasis Day ...
... 24, 2011 HealthWarehouse.com, Inc. (OTC: HEWA), a ... it will begin providing prescription medications for WhiteGlove ... "We,re excited to have a national partner ... areas," said Robert Fabbio, co-founder and chief executive ...
Cached Medicine Technology:PhotoMedex Increases Access to Care for Children in Recognition of World Psoriasis Day, Oct. 29 2PhotoMedex Increases Access to Care for Children in Recognition of World Psoriasis Day, Oct. 29 3PhotoMedex Increases Access to Care for Children in Recognition of World Psoriasis Day, Oct. 29 4WhiteGlove Health Selects HealthWarehouse.com to Provide Prescription Medications to its Members Nationwide 2
(Date:7/10/2014)... July 10, 2014 Ticketability.com has a wide ... now Paul McCartney tickets for San Diego are being added ... Diego since 1976, and the newly added September 28 show ... , Click Here to view the selection of ... Petco Park will become available to the general public on ...
(Date:7/10/2014)... D.C. (PRWEB) July 10, 2014 One ... for Bangladesh Worker Safety announced today it will extend ... to four months’ wages for workers displaced as a ... To date, Alliance inspections have resulted in the closure ... in all five cases, raising immediate safety concerns. In ...
(Date:7/10/2014)... 2014 According to a new ... Platforms (Land, Airborne, Naval), Application (Software Defined Radios, ... Geography (North America, Asia-Pacific, Europe, the Middle East ... by MarketsandMarkets, the market is estimated to be ... register a CAGR of 5.56% to reach $39.52 ...
(Date:7/10/2014)... In his latest blog post at http://www.perwickstrom.com , ... Wickstrom has listed 5 ways to follow-up without being ... get information or sometimes even just return an inquiry, ... a skill that most people don’t have,” commented Per ... dialogue moving without coming across as annoying – let ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 A ... program that gets clients off to a great start ... can believe in, has launched a new Eating Disorders ... The new section highlights:, , Different ... Statistic Manual of Mental Disorders (DSM-IV), including anorexia nervosa, ...
Breaking Medicine News(10 mins):Health News:Paul McCartney Tickets for San Diego: Ticketability.com Announces Discounted Tickets for McCartney’s Tour Stop at Petco Park on September 28 2Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Per Wickstrom’s Latest Blog Post Lists 5 Ways to Follow-up Without Being Annoying 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2
... May 15 Gerson Lehrman Group, the world,s,leading ... a Web-based community devoted to providing patients with ... own healthcare.,iGuard.org provides personalized iGuard Risk Ratings, iGuard ... their experience with other registered,users who also want ...
... of healthcare and medical device experience to board ... of fast-growing ... the first and only flexible CO2 laser scalpel enabling new procedures ... to the company,s board of directors. Suennen, co-founder and,managing member of ...
... /Xinhua-PRNewswire/ -- Tiens Biotech Group (USA), Inc.,(the ,Company, or ,Tiens,), ... for the first quarter ended March 31, 2008., Revenue ... to,$16.2 million for the first quarter of 2007., Net ... or $0.05 per,share, compared to net income of $6.5 million, ...
... a Cranergy(TM) ... Fuel Station in NYC,s Penn Station, LAKEVILLE-MIDDLEBORO, Mass., May ... country and lift people from,America,s other energy crisis. With hectic, ... at multi-tasking, most,people need an extra boost to keep them ...
... of altruism; helping others ... one,s own health issues, CHICAGO, May 15 Meet Cindy Zamirowski, ... "cancer,free" thumbs up from her physician, stepped off the curb to raise ... The Bolingbrook mom of three and grandma of three rallied her ...
... DURHAM, N.C. -- By targeting and disabling a protein frequently ... the cancer more vulnerable to chemotherapy, according to a new ... We tested a compound that can weaken the tumor by ... cell. When chemotherapy was applied to the tumor in this ...
Cached Medicine News:Health News:Gerson Lehrman Group and iGuard, Inc. Partner to Offer Patients a Voice in Healthcare Industry Decisions 2Health News:Gerson Lehrman Group and iGuard, Inc. Partner to Offer Patients a Voice in Healthcare Industry Decisions 3Health News:Lisa M. Suennen Joins OmniGuide(R) Board of Directors 2Health News:Tiens Biotech Group (USA) Reports First Quarter Results 2Health News:Tiens Biotech Group (USA) Reports First Quarter Results 3Health News:Tiens Biotech Group (USA) Reports First Quarter Results 4Health News:Tiens Biotech Group (USA) Reports First Quarter Results 5Health News:Tiens Biotech Group (USA) Reports First Quarter Results 6Health News:Tiens Biotech Group (USA) Reports First Quarter Results 7Health News:Tiens Biotech Group (USA) Reports First Quarter Results 8Health News:Tiens Biotech Group (USA) Reports First Quarter Results 9Health News:Tiens Biotech Group (USA) Reports First Quarter Results 10Health News:Tiens Biotech Group (USA) Reports First Quarter Results 11Health News:Video: Ocean Spray Revitalizes Americans Naturally With Free Fuel for Their Bodies 2Health News:After Effects: Giving Back Is Good for You 2Health News:Targeted therapy plus chemotherapy may pack 1-2 punch against melanoma 2
... helps you deliver unmatched performance through patient-focused ... the most complete anesthesia solution developed, putting ... - at your fingertips., ,The Aisys ... legacy of anesthesia delivery and patient monitoring ...
... Premilene Mesh LP Self-Forming Plug is combining ... This results in a very soft hernia plug ... to standard Plugs less foreign body material is ... the hernia size and shape allows for a ...
... Celsius Control System provides physicians,with ... safely,and rapidly lower patient body ... temperature and,rewarm patients to normothermic ... consists of an endovascular,catheter, console ...
... Fiberoptics Gemini surgical headlight is perfectly balanced ... durable and ultra-low-profile and illuminates brilliantly while ... annoying "rams effect." The fully adjustable headband, ... to sit low on the brow, directing ...
Medicine Products: